{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:47:02Z","timestamp":1789955222719,"version":"4.0.1"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,8,17]]},"DOI":"10.1093\/jnci\/dji242","type":"journal-article","created":{"date-parts":[[2005,8,16]],"date-time":"2005-08-16T20:33:13Z","timestamp":1124224393000},"page":"1221-1224","source":"Crossref","is-referenced-by-count":199,"title":["Cetuximab Therapy and Symptomatic Hypomagnesemia"],"prefix":"10.1093","volume":"97","author":[{"given":"Deborah","family":"Schrag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Young","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Flombaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Saltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,8,17]]},"reference":[{"key":"key\n\t\t\t\t20171012210017_BIB1","doi-asserted-by":"crossref","unstructured":"Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. \n            J Clin Oncol2003\n            ;\n            21\n            :\n            2787\n            \u201399.","DOI":"10.1200\/JCO.2003.01.504"},{"key":"key\n\t\t\t\t20171012210017_BIB2","unstructured":"Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. \n            J Clin Oncol2002\n            ;\n            20\n            (18 Suppl):\n            1S\n            \u201313S."},{"key":"key\n\t\t\t\t20171012210017_BIB3","unstructured":"Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. \n            Clin Cancer Res2002\n            ;\n            8\n            :\n            994\n            \u20131003."},{"key":"key\n\t\t\t\t20171012210017_BIB4","doi-asserted-by":"crossref","unstructured":"Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. \n            J Clin Oncol2004\n            ;\n            22\n            :\n            1201\n            \u20138.","DOI":"10.1200\/JCO.2004.10.182"},{"key":"key\n\t\t\t\t20171012210017_BIB5","doi-asserted-by":"crossref","unstructured":"Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. \n            N Engl J Med2004\n            ;\n            351\n            :\n            337\n            \u201345.","DOI":"10.1056\/NEJMoa033025"},{"key":"key\n\t\t\t\t20171012210017_BIB6","doi-asserted-by":"crossref","unstructured":"Lajer H, Daugaard G. Cisplatin and hypomagnesemia. \n            Cancer Treat Rev1999\n            ;\n            25\n            :\n            47\n            \u201358.","DOI":"10.1053\/ctrv.1999.0097"},{"key":"key\n\t\t\t\t20171012210017_BIB7","doi-asserted-by":"crossref","unstructured":"Whang R, Hampton EM, Whang DD. Magnesium homeostasis and clinical disorders of magnesium deficiency. \n            Ann Pharmacother1994\n            ;\n            28\n            :\n            220\n            \u20136.","DOI":"10.1177\/106002809402800213"},{"key":"key\n\t\t\t\t20171012210017_BIB8","unstructured":"Kelepouris E, Agus ZS. Hypomagnesemia: renal magnesium handling. \n            Semin Nephrol1998\n            ;\n            18\n            :\n            58\n            \u201373."},{"key":"key\n\t\t\t\t20171012210017_BIB9","doi-asserted-by":"crossref","unstructured":"Schlingmann KP, Weber S, Peters M, Niemann Nejsum L, Vitzthum H, Klingel K, et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. \n            Nat Genet2002\n            ;\n            31\n            :\n            166\n            \u201370.","DOI":"10.1038\/ng889"},{"key":"key\n\t\t\t\t20171012210017_BIB10","doi-asserted-by":"crossref","unstructured":"Chubanov V, Waldegger S, Mederos y Schnitzler M, Vitzthum H, Sassen MC, Seyberth HW, et al. Disruption of TRPM6\/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia. \n            Proc Natl Acad Sci USA2004\n            ;\n            101\n            :\n            2894\n            \u20139.","DOI":"10.1073\/pnas.0305252101"},{"key":"key\n\t\t\t\t20171012210017_BIB11","doi-asserted-by":"crossref","unstructured":"Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. \n            J Clin Oncol2004\n            ;\n            22\n            :\n            175\n            \u201384.","DOI":"10.1200\/JCO.2004.05.114"},{"key":"key\n\t\t\t\t20171012210017_BIB12","unstructured":"National Cancer Institute Common Toxicity and Adverse Event Criteria for Serum Calcium and Magnesium. Available at: \n            http:\/\/ctep.cancer.gov\/forms\/CTCAEV3.pdf\n             (last accessed: May 5, \n            2005\n            )."},{"key":"key\n\t\t\t\t20171012210017_BIB13","doi-asserted-by":"crossref","unstructured":"Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. \n            J Clin Oncol2004\n            ;\n            22\n            :\n            229\n            \u201337.","DOI":"10.1200\/JCO.2004.05.113"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/97\/16\/1221\/7686458\/dji242.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T01:00:46Z","timestamp":1507856446000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jnci\/article\/97\/16\/1221\/2521344\/Cetuximab-Therapy-and-Symptomatic-Hypomagnesemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,17]]},"references-count":13,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2005,8,17]]},"published-print":{"date-parts":[[2005,8,17]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/dji242","relation":{},"ISSN":["1460-2105","0027-8874"],"issn-type":[{"value":"1460-2105","type":"electronic"},{"value":"0027-8874","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,8,17]]},"published":{"date-parts":[[2005,8,17]]}}}